84 results on '"Plass K"'
Search Results
2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
- Author
-
Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.
- Published
- 2019
- Full Text
- View/download PDF
3. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
- Author
-
Beijert, I.J., primary, Hentschel, A.E., additional, Bründl, J., additional, Compérat, E.M, additional, Plass, K., additional, Rodríguez, O., additional, Subiela Henríquez, J.D., additional, Hernández, V., additional, De La Peña, E., additional, Alemany, I., additional, Turturica, D., additional, Pisano, F., additional, Soria, F., additional, Čapoun, O., additional, Bauerová, L., additional, Pešl, M., additional, Bruins, H.M., additional, Runneboom, W., additional, Herdegen, S., additional, Breyer, J., additional, Brisuda, A., additional, Calatrava, A., additional, Rubio-Briones, J.., additional, Seles, M., additional, Mannweiler, S., additional, Bosschieter, J., additional, Kusuma, V.R.M., additional, Ashabere, D., additional, Huebner, N., additional, Cotte, J., additional, Mertens, L.S, additional, Masson-Lecomte, A., additional, Liedberg, F., additional, Cohen, D., additional, Lunelli, L., additional, Cussenot, O., additional, El Sheikh, S., additional, Volanis, D., additional, Côté, J., additional, Rouprêt, M., additional, Haitel, A., additional, Shariat, S.F., additional, Mostafid, A.H., additional, Nieuwenhuijzen, J.A., additional, Zigeuner, R., additional, Dominguez-Escrig, J.L., additional, Hacek, J., additional, Zlotta, A.R., additional, Burger, M., additional, Evert, M., additional, Hulsbergen - Van De Kaa, C.A., additional, Van Der Heijden, A.G., additional, Kiemeney, L.A.L.M., additional, Soukup, V., additional, Molinaro, L., additional, Gontero, P., additional, Llorente, C., additional, Algaba, F., additional, Palou, J., additional, N’Dow, J., additional, Ribal, M.J., additional, Van Der Kwast, T.H., additional, Babjuk, M., additional, Sylvester, R.J., additional, and Van Rhijn, B.W.G., additional
- Published
- 2022
- Full Text
- View/download PDF
4. O3 - Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
- Author
-
Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M, Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., De La Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J.., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S, Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., El Sheikh, S., Volanis, D., Côté, J., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen - Van De Kaa, C.A., Van Der Heijden, A.G., Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N’Dow, J., Ribal, M.J., Van Der Kwast, T.H., Babjuk, M., Sylvester, R.J., and Van Rhijn, B.W.G.
- Published
- 2022
- Full Text
- View/download PDF
5. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer
- Author
-
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comperat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmuller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinos E, Logager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Muller AC, Muller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupret M, Rouviere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van der Heijden AG, Van Poppel H, Vartolomei MD, Veskimae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A, Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A., UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, Ja, Babjuk, M, Bellmunt, J, Bruins, Hm, De Reijke, Tm, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, Mj, Shariat, Sf, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, Pc, Bochner, Bh, Bolla, M, Boormans, Jl, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, Pjl, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, Jl, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, Jj, Gakis, G, Geavlete, B, Gontero, P, Grubmuller, B, Hafeez, S, Hansel, De, Hartmann, A, Hayne, D, Henry, Am, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, Ba, Jones, R, Kamat, Am, Khoo, V, Kiltie, Ae, Krege, S, Ladoire, S, Lara, Pc, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, Mc, Moschini, M, Mostafid, H, Muller, Ac, Muller, Cr, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, Jr, Oldenburg, J, Osanto, S, Oyen, Wjg, Pacheco-Figueiredo, L, Pappot, H, Patel, Mi, Pieters, Br, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, Je, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, Rj, Smits, A, Stenzl, A, Thalmann, Gn, Tombal, B, Turkbey, B, Lauridsen, Sv, Valdagni, R, Van der Heijden, Ag, Van Poppel, H, Vartolomei, Md, Veskimae, E, Vilaseca, A, Rivera, Fav, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A
- Subjects
Treatment ,Consensus ,Follow-up ,education ,Bladder cancer ,Diagnosis ,Consensu ,Delphi ,Diagnosi - Abstract
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.Setting: Online Delphi survey and consensus conference.Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as >= 70% agreement and
- Published
- 2020
6. Mapping EAU guideline practice variations across Europe: An audit of ADT before surgery in locally advanced and high-risk prostate cancer in 6315 cases across 31 European countries
- Author
-
MacLennan, S., primary, Azevedo, N., additional, Briganti, A., additional, Duncan, E., additional, Dunsmore, J., additional, Fullwood, L., additional, Lumen, N., additional, Plass, K., additional, Ribal, M.J., additional, Roobol, M.J., additional, Schouten, N., additional, Smith, E.J., additional, Skolarus, T.A., additional, and N'Dow, J.M.O., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Introducing PIONEER: a project to harness big data in prostate cancer research
- Author
-
Omar M. I., Roobol M. J., Ribal M. J., Abbott T., Agapow P. -M., Araujo S., Asiimwe A., Auffray C., Balaur I., Beyer K., Bernini C., Bjartell A., Briganti A., Butler-Ransohoff J. -E., Campi R., Cavelaars M., De Meulder B., Devecseri Z., Voss M. D., Dimitropoulos K., Evans-Axelsson S., Franks B., Fullwood L., Horgan D., Smith E. J., Kiran A., Kivinummi K., Lambrecht M., Lancet D., Lindgren P., MacLennan S., Nogueira M. M., Moen F., Moinat M., Papineni K., Reich C., Reiche K., Rogiers S., Sartini C., van Bochove K., van Diggelen F., Van Hemelrijck M., Van Poppel H., Zong J., N'Dow J., Andersson E., Arala H., Auvinen A., Bangma C., Burke D., Cardone A., Casariego J., Cuperus G., Dabestani S., Esperto F., Fossati N., Fridhammar A., Gandaglia G., Tandefelt D. G., Horn F., Huber J., Hugosson J., Huisman H., Josefsson A., Kilkku O., Kreuz M., Lardas M., Lawson J., Lefresne F., Lejeune S., Longden-Chapman E., McVie G., Moris L., Mottet N., Murtola T., Nicholls C., Pang K. H., Pascoe K., Picozzi M., Plass K., Pohjanjousi P., Reaney M., Remmers S., Robinson P., Schalken J., Schravendeel M., Seisen T., Servan A., Shiranov K., Snijder R., Steinbeisser C., Taibi N., Talala K., Tilki D., Van den Broeck T., Vassilev Z., Voima O., Vradi E., Waldeck R., Weistra W., Willemse P. -P., Wirth M., Wolfinger R., Kermani N. Z., Omar, M. I., Roobol, M. J., Ribal, M. J., Abbott, T., Agapow, P. -M., Araujo, S., Asiimwe, A., Auffray, C., Balaur, I., Beyer, K., Bernini, C., Bjartell, A., Briganti, A., Butler-Ransohoff, J. -E., Campi, R., Cavelaars, M., De Meulder, B., Devecseri, Z., Voss, M. D., Dimitropoulos, K., Evans-Axelsson, S., Franks, B., Fullwood, L., Horgan, D., Smith, E. J., Kiran, A., Kivinummi, K., Lambrecht, M., Lancet, D., Lindgren, P., Maclennan, S., Nogueira, M. M., Moen, F., Moinat, M., Papineni, K., Reich, C., Reiche, K., Rogiers, S., Sartini, C., van Bochove, K., van Diggelen, F., Van Hemelrijck, M., Van Poppel, H., Zong, J., N'Dow, J., Andersson, E., Arala, H., Auvinen, A., Bangma, C., Burke, D., Cardone, A., Casariego, J., Cuperus, G., Dabestani, S., Esperto, F., Fossati, N., Fridhammar, A., Gandaglia, G., Tandefelt, D. G., Horn, F., Huber, J., Hugosson, J., Huisman, H., Josefsson, A., Kilkku, O., Kreuz, M., Lardas, M., Lawson, J., Lefresne, F., Lejeune, S., Longden-Chapman, E., Mcvie, G., Moris, L., Mottet, N., Murtola, T., Nicholls, C., Pang, K. H., Pascoe, K., Picozzi, M., Plass, K., Pohjanjousi, P., Reaney, M., Remmers, S., Robinson, P., Schalken, J., Schravendeel, M., Seisen, T., Servan, A., Shiranov, K., Snijder, R., Steinbeisser, C., Taibi, N., Talala, K., Tilki, D., Van den Broeck, T., Vassilev, Z., Voima, O., Vradi, E., Waldeck, R., Weistra, W., Willemse, P. -P., Wirth, M., Wolfinger, R., Kermani, N. Z., Publica, and Urology
- Subjects
0301 basic medicine ,Prioritization ,Knowledge management ,Urology ,media_common.quotation_subject ,education ,Big data ,Disease ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Multidisciplinary approach ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,Medicine ,Quality (business) ,media_common ,business.industry ,Patient-centered outcomes ,medicine.disease ,3. Good health ,Patient management ,030104 developmental biology ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,030220 oncology & carcinogenesis ,business - Abstract
Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. In this Perspectives article, the authors introduce the PIONEER project and describe its aims and plans for ultimately improving prostate cancer care through the use of big data.
- Published
- 2020
8. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research (Nature Reviews Urology, (2020), 17, 6, (351-362), 10.1038/s41585-020-0324-x)
- Author
-
Omar M. I., Roobol M. J., Ribal M. J., Abbott T., Agapow P. -M., Araujo S., Asiimwe A., Auffray C., Balaur I., Beyer K., Bernini C., Bjartell A., Briganti A., Butler-Ransohoff J. -E., Campi R., Cavelaars M., De Meulder B., Devecseri Z., Voss M. D., Dimitropoulos K., Evans-Axelsson S., Franks B., Fullwood L., Horgan D., Smith E. J., Kiran A., Kivinummi K., Lambrecht M., Lancet D., Lindgren P., MacLennan S., Nogueira M. M., Moen F., Moinat M., Papineni K., Reich C., Reiche K., Rogiers S., Sartini C., van Bochove K., van Diggelen F., Van Hemelrijck M., Van Poppel H., Zong J., N'Dow J., Andersson E., Arala H., Auvinen A., Bangma C., Burke D., Cardone A., Casariego J., Cuperus G., Dabestani S., Esperto F., Fossati N., Fridhammar A., Gandaglia G., Tandefelt D. G., Horn F., Huber J., Hugosson J., Huisman H., Josefsson A., Kilkku O., Kreuz M., Lardas M., Lawson J., Lefresne F., Lejeune S., Longden-Chapman E., McVie G., Moris L., Mottet N., Murtola T., Nicholls C., Pang K. H., Pascoe K., Picozzi M., Plass K., Pohjanjousi P., Reaney M., Remmers S., Robinson P., Schalken J., Schravendeel M., Seisen T., Servan A., Shiranov K., Snijder R., Steinbeisser C., Taibi N., Talala K., Tilki D., Van den Broeck T., Vassilev Z., Voima O., Vradi E., Waldeck R., Weistra W., Willemse P. -P., Wirth M., Wolfinger R., Kermani N. Z., Omar, M. I., Roobol, M. J., Ribal, M. J., Abbott, T., Agapow, P. -M., Araujo, S., Asiimwe, A., Auffray, C., Balaur, I., Beyer, K., Bernini, C., Bjartell, A., Briganti, A., Butler-Ransohoff, J. -E., Campi, R., Cavelaars, M., De Meulder, B., Devecseri, Z., Voss, M. D., Dimitropoulos, K., Evans-Axelsson, S., Franks, B., Fullwood, L., Horgan, D., Smith, E. J., Kiran, A., Kivinummi, K., Lambrecht, M., Lancet, D., Lindgren, P., Maclennan, S., Nogueira, M. M., Moen, F., Moinat, M., Papineni, K., Reich, C., Reiche, K., Rogiers, S., Sartini, C., van Bochove, K., van Diggelen, F., Van Hemelrijck, M., Van Poppel, H., Zong, J., N'Dow, J., Andersson, E., Arala, H., Auvinen, A., Bangma, C., Burke, D., Cardone, A., Casariego, J., Cuperus, G., Dabestani, S., Esperto, F., Fossati, N., Fridhammar, A., Gandaglia, G., Tandefelt, D. G., Horn, F., Huber, J., Hugosson, J., Huisman, H., Josefsson, A., Kilkku, O., Kreuz, M., Lardas, M., Lawson, J., Lefresne, F., Lejeune, S., Longden-Chapman, E., Mcvie, G., Moris, L., Mottet, N., Murtola, T., Nicholls, C., Pang, K. H., Pascoe, K., Picozzi, M., Plass, K., Pohjanjousi, P., Reaney, M., Remmers, S., Robinson, P., Schalken, J., Schravendeel, M., Seisen, T., Servan, A., Shiranov, K., Snijder, R., Steinbeisser, C., Taibi, N., Talala, K., Tilki, D., Van den Broeck, T., Vassilev, Z., Voima, O., Vradi, E., Waldeck, R., Weistra, W., Willemse, P. -P., Wirth, M., Wolfinger, R., and Kermani, N. Z.
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
9. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
- Author
-
Witjes, J.A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. De Blok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Mir, M.C. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Lauridsen, S.V. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Rivera, F.A.V. Wiegel, T. Wiklund, P. Willemse, P.-P.M. Williams, A. Zigeuner, R. Horwich, A.
- Abstract
The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands © 2019 European Society of Medical Oncology and European Association of Urology
- Published
- 2020
10. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees
- Author
-
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.
- Subjects
Consensus ,Follow-up ,education ,Bladder cancer ,Diagnosis ,Treatment ,Delphi - Abstract
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.
- Published
- 2020
11. P119 - Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?
- Author
-
Hentschel, A.E., Van Rhijn, B.W.G., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., De La Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Scavarda-Lamberti, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Cohen, D., Lunelli, L., Cussenot, O., El Sheikh, S., Volanis, D., Coté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen - Van De Kaa, C.A., Van Der Heijden, A.G., Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N’dow, J., Babjuk, M., Van Der Kwast, T.H., and Sylvester, R.J.
- Published
- 2019
- Full Text
- View/download PDF
12. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for active surveillance for localised prostate cancer from an international collaborative study (DETECTIVE study)
- Author
-
Lam, T.B., primary, MacLennan, S.J., additional, Willemse, P-P., additional, Mason, M.D., additional, Plass, K., additional, Shepherd, R., additional, Cornford, P., additional, and Mottet, N., additional
- Published
- 2020
- Full Text
- View/download PDF
13. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?
- Author
-
Hentschel, A.E., primary, Van Rhijn, B.W.G., additional, Bründl, J., additional, Compérat, E.M., additional, Plass, K., additional, Rodríguez, O., additional, Subiela Henríquez, J.D., additional, Hernández, V., additional, De La Peña, E., additional, Alemany, I., additional, Turturica, D., additional, Pisano, F., additional, Soria, F., additional, Čapoun, O., additional, Bauerová, L., additional, Pešl, M., additional, Bruins, H.M., additional, Runneboom, W., additional, Herdegen, S., additional, Breyer, J., additional, Brisuda, A., additional, Scavarda-Lamberti, A., additional, Calatrava, A., additional, Rubio-Briones, J., additional, Seles, M., additional, Mannweiler, S., additional, Bosschieter, J., additional, Kusuma, V.R.M., additional, Ashabere, D., additional, Huebner, N., additional, Cotte, J., additional, Mertens, L.S., additional, Cohen, D., additional, Lunelli, L., additional, Cussenot, O., additional, El Sheikh, S., additional, Volanis, D., additional, Coté, J.F., additional, Rouprêt, M., additional, Haitel, A., additional, Shariat, S.F., additional, Mostafid, A.H., additional, Nieuwenhuijzen, J.A., additional, Zigeuner, R., additional, Dominguez-Escrig, J.L., additional, Hacek, J., additional, Zlotta, A.R., additional, Burger, M., additional, Evert, M., additional, Hulsbergen - Van De Kaa, C.A., additional, Van Der Heijden, A.G., additional, Kiemeney, L.A.L.M., additional, Soukup, V., additional, Molinaro, L., additional, Gontero, P., additional, Llorente, C., additional, Algaba, F., additional, Palou, J., additional, N’dow, J., additional, Babjuk, M., additional, Van Der Kwast, T.H., additional, and Sylvester, R.J., additional
- Published
- 2019
- Full Text
- View/download PDF
14. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
- Author
-
Horwich, A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. DeBlok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Carmen Mir, M. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Vahr Lauridsen, S. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Vives Rivera, F.A. Wiegel, T. Wiklund, P. Williams, A. Zigeuner, R. Witjes, J.A.
- Subjects
education - Abstract
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © 2019 European Society for Medical Oncology
- Published
- 2019
15. PT075 - Care pathways for the management of localised and locally advanced prostate cancer: Experience of the EAU guidelines office
- Author
-
Dimitropoulos, K., Cornford, P., De Santis, M., Mason, M., Rouviere, O., Bolla, M., Briganti, A., Fossati, N., Gandaglia, G., Maclennan, S., N’Dow, J., Omar, I., Plass, K., Royle, J., Van Den Bergh, R., Van Der Poel, H., Wiegel, T., and Mottet, N.
- Published
- 2018
- Full Text
- View/download PDF
16. 71 - Care pathways for the management of metastatic and castration-resistant prostate cancer in the era of novel therapeutic options: Experience of the EAU guidelines office
- Author
-
Dimitropoulos, K., De Santis, M., Mason, M., Cornford, P., Rouviere, O., Bolla, M., Briganti, A., Fossati, N., Gandaglia, G., Maclennan, S., N’Dow, J., Omar, I., Plass, K., Royle, J., Van Den Bergh, R., Van Der Poel, H., Wiegel, T., and Mottet, N.
- Published
- 2018
- Full Text
- View/download PDF
17. A0959 - Mapping EAU guideline practice variations across Europe: An audit of ADT before surgery in locally advanced and high-risk prostate cancer in 6315 cases across 31 European countries
- Author
-
MacLennan, S., Azevedo, N., Briganti, A., Duncan, E., Dunsmore, J., Fullwood, L., Lumen, N., Plass, K., Ribal, M.J., Roobol, M.J., Schouten, N., Smith, E.J., Skolarus, T.A., and N'Dow, J.M.O.
- Published
- 2022
- Full Text
- View/download PDF
18. An international collaborative study to develop consensus statements for deferred treatment with curative intent for localised prostate cancer
- Author
-
MacLennan, S., primary, Lam, T.B., additional, Irani, J., additional, Plass, K., additional, Willemse, P.M., additional, Mason, M., additional, Cornford, P., additional, N’Dow, J., additional, Van Poppel, H.P.A.M., additional, and Mottet, N., additional
- Published
- 2019
- Full Text
- View/download PDF
19. The role of care pathways in urology: Vision of the European Association of Urology Guidelines Office
- Author
-
Dimitropoulos, K., primary, Ribal, M.J., additional, van der Velden, A., additional, Plass, K., additional, Shepherd, R., additional, N’Dow, J., additional, and Omar, M.I., additional
- Published
- 2019
- Full Text
- View/download PDF
20. Care pathways for the management of metastatic and castration-resistant prostate cancer in the era of novel therapeutic options: Experience of the EAU guidelines office
- Author
-
Dimitropoulos, K., primary, De Santis, M., additional, Mason, M., additional, Cornford, P., additional, Rouviere, O., additional, Bolla, M., additional, Briganti, A., additional, Fossati, N., additional, Gandaglia, G., additional, Maclennan, S., additional, N’Dow, J., additional, Omar, I., additional, Plass, K., additional, Royle, J., additional, Van Den Bergh, R., additional, Van Der Poel, H., additional, Wiegel, T., additional, and Mottet, N., additional
- Published
- 2018
- Full Text
- View/download PDF
21. How to resolve discrepancies when findings from randomized controlled trials and meta-analyses disagree?
- Author
-
Sylvester, R.J., primary, Canfield, S.E., additional, Lam, T.B.L., additional, Marconi, L., additional, MacLennan, S., additional, Yuan, Y., additional, MacLennan, G., additional, Norrie, J., additional, Omar, M.I., additional, Bruins, H.M., additional, Hernández, V., additional, Plass, K., additional, Van Poppel, H., additional, and N’Dow, J., additional
- Published
- 2018
- Full Text
- View/download PDF
22. Care pathways for the management of localised and locally advanced prostate cancer: Experience of the EAU guidelines office
- Author
-
Dimitropoulos, K., primary, Cornford, P., additional, De Santis, M., additional, Mason, M., additional, Rouviere, O., additional, Bolla, M., additional, Briganti, A., additional, Fossati, N., additional, Gandaglia, G., additional, Maclennan, S., additional, N’Dow, J., additional, Omar, I., additional, Plass, K., additional, Royle, J., additional, Van Den Bergh, R., additional, Van Der Poel, H., additional, Wiegel, T., additional, and Mottet, N., additional
- Published
- 2018
- Full Text
- View/download PDF
23. PT346 - The role of care pathways in urology: Vision of the European Association of Urology Guidelines Office
- Author
-
Dimitropoulos, K., Ribal, M.J., van der Velden, A., Plass, K., Shepherd, R., N’Dow, J., and Omar, M.I.
- Published
- 2019
- Full Text
- View/download PDF
24. PT340 - An international collaborative study to develop consensus statements for deferred treatment with curative intent for localised prostate cancer
- Author
-
MacLennan, S., Lam, T.B., Irani, J., Plass, K., Willemse, P.M., Mason, M., Cornford, P., N’Dow, J., Van Poppel, H.P.A.M., and Mottet, N.
- Published
- 2019
- Full Text
- View/download PDF
25. PT004 - How to resolve discrepancies when findings from randomized controlled trials and meta-analyses disagree?
- Author
-
Sylvester, R.J., Canfield, S.E., Lam, T.B.L., Marconi, L., MacLennan, S., Yuan, Y., MacLennan, G., Norrie, J., Omar, M.I., Bruins, H.M., Hernández, V., Plass, K., Van Poppel, H., and N’Dow, J.
- Published
- 2018
- Full Text
- View/download PDF
26. Conformational Pseudopolymorphism and Orientational Disorder in Two-Dimensional Alkyl Carbamate Crystals
- Author
-
Kim, K., Plass, K. E., and Matzger, A. J.
- Abstract
The structures of self-assembled physisorbed monolayers of alkyl carbamates were examined with atomic detail by scanning tunneling microscopy at the liquid−solid interface. Through systematic variation of molecular structure, the factors determining the two-dimensional crystal packing and dynamics of alkyl carbamate monolayers were isolated. Two different conformational pseudopolymorphs on the surface were observed and their order of stability was varied by changing the length of the alkyl groups. The relative size of the two alkyl groups in a molecule affected the frequency of orientational flipping within a column, which in turn, exerts an influence on the relative orientation of the two-dimensional crystalline domains. These phenomena were explained on the basis of the preferred hydrogen-bonding geometry of the carbamate functional group and the different degree of van der Waals interaction for each form.
- Published
- 2005
27. Single-Phase Synthesis of Functionalized Gold Nanoparticles
- Author
-
Rowe, M. P., Plass, K. E., Kim, K., Kurdak, C., Zellers, E. T., and Matzger, A. J.
- Abstract
A single-phase synthesis of thiolate monolayer-protected gold clusters (MPCs) is described. This method avoids the problem of persistent ionic contamination from residual phase-transfer catalyst while retaining the versatility associated with the commonly used two-phase Brust synthesis. MPCs having alkyl, diphenylacetylene, ether, amide, or ester functionalities were prepared by this single-phase synthesis and characterized via 1H NMR, FT-IR, and UV−vis absorption spectroscopy, TGA, STM, and TEM. Comparisons of products synthesized by this method and by existing methods are made for a subset of MPCs. Results are considered in the context of using MPC thin films as chemically sensitive interface layers in chemiresistor vapor sensors.
- Published
- 2004
28. Kinetic and Thermodynamic Forms of a Two-Dimensional Crystal
- Author
-
Kim, K., Plass, K. E., and Matzger, A. J.
- Abstract
The first examples of self-assembled physisorbed monolayers containing a carbamate functional group have been imaged with atomic resolution by scanning tunneling microscopy. Two different conformational pseudopolymorphs and a clear structural transition between these packing structures are observed. Each of these minima is characterized by a different degree of van der Waals and electrostatic interactions. In addition, one of these modifications shows a pseudoperiodic change of column direction resulting from disordering of the packing structure associated with orientational flipping of the molecules. The phase transition behavior can be understood in the context of Ostwald's rule of stages, a widely observed phenomenon in three-dimensional crystallizations.
- Published
- 2003
29. Acoustic Surface Wave Band-Stop Filter for UHF Frequencies.
- Author
-
Plass, K. G.
- Published
- 1973
- Full Text
- View/download PDF
30. Terminals, Minicomputer und Großrechner in DCA-Netzwerken
- Author
-
PLASS, K.
- Published
- 1981
- Full Text
- View/download PDF
31. A New Ultrasonic Flowmeter for Intravascular Application.
- Author
-
Plass, K. G.
- Published
- 1964
- Full Text
- View/download PDF
32. Acoustic Surface Wave Band-Stop Filter for UHF Frequencies
- Author
-
Plass, K. G., primary
- Published
- 1973
- Full Text
- View/download PDF
33. Sound Absorption in Liquid Acetic Acid in the Frequency Range Between 0.3 to 1.5 GHz
- Author
-
Bader, F., primary and Plaß, K. G., additional
- Published
- 1971
- Full Text
- View/download PDF
34. Vibrational relaxation in liquids
- Author
-
Plass, K. G., primary
- Published
- 1970
- Full Text
- View/download PDF
35. ChemInform Abstract: SCHWINGUNGSRELAXATION IN FLUESSIGKEITEN
- Author
-
PLASS, K. G., primary
- Published
- 1970
- Full Text
- View/download PDF
36. ChemInform Abstract: SCHALLABSORPTION IN FLUESSIGER ESSIGSAEURE IM FREQUENZBEREICH VON 0,3 BIS 1,5 GHZ
- Author
-
BADER, F., primary and PLASS, K. G., additional
- Published
- 1971
- Full Text
- View/download PDF
37. A New Ultrasonic Flowmeter for Intravascular Application
- Author
-
Plass, K. G.
- Abstract
An instrument for the measurement of pulsatile blood flow has been developed. The device uses a small probe suitable for intravascular insertion, and the method of measurement employs a combination of ultrasonic pulse techniques and phase detection.
- Published
- 1966
- Full Text
- View/download PDF
38. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort
- Author
-
Antoine G. van der Heijden, Konstantinos Dimitropoulos, Joost L. Boormans, Bogdan Geavlete, Iris Brummelhuis, Andrew K. Williams, Christoph R. Müller, Susanne Vahr Lauridsen, Arturo Chiti, Manish I. Patel, Jonathan E. Rosenberg, Baris Turkbey, Carl Salembier, Thomas Wiegel, Anja Lorch, Valérie Fonteyne, Willem de Blok, Evanguelos Xylinas, Antti Salminen, Ann Henry, Karin Plass, Amir Sherif, Hugh Mostafid, Peter Wiklund, Erik Veskimäe, Hein Van Poppel, Max Bürger, Juan Palou, J. Domínguez-Escrig, Karel Decaestecker, Morgan Rouprêt, Helle Pappot, Paul Sargos, Berardino De Bari, Riccardo Valdagni, Luís Pacheco-Figueiredo, Jorge Huguet, Silke Gillessen, Olivier Rouvière, Maria J. Ribal, Yann Neuzillet, Richard Cathomas, Shaista Hafeez, Robert Jan Smeenk, Mark Frydenberg, Marek Babjuk, Antoni Vilaseca, Maria De Santis, Jonathan Richenberg, Annemarie Leliveld, Tom J.H. Arends, Shomik Sengupta, Vibeke Løgager, Harry W. Herr, Wim J.G. Oyen, Ananya Choudhury, Nicholas D. James, Susanne Osanto, Shahrokh F. Shariat, Vincent Khoo, A. Müller, Neeraj Agarwal, Pieter De Visschere, Bradley R. Pieters, Alberto Briganti, Robert Jones, Peter C. Black, Alberto Bossi, H. Maxim Bruins, Richard P. Meijer, Bertrand Tombal, Ken Herrmann, Donna E. Hansel, M. Carmen Mir, Stéphane Culine, J. Alfred Witjes, Virginia Hernández, Joaquim Bellmunt, Arnulf Stenzl, Eva Compérat, Alan Horwich, Alison Birtle, Jorg R. Oddens, Bernhard Grubmüller, Margitta Retz, Sylvain Ladoire, Marco Moschini, Aristotle Bamias, Simon J. Crabb, Michel Bolla, Theo H. van der Kwast, Steven MacLennan, Michael Rink, Anita Smits, Yohann Loriot, Estefania Linares-Espinós, James N'Dow, Theo M. de Reijke, Thomas Powles, Jurgen J. Fütterer, Arndt Hartmann, Daniel Castellano, Mesut Remzi, Paolo Gontero, Dickon Hayne, Anne E. Kiltie, Richard Zigeuner, Georgios Gakis, Franklin A. Vives Rivera, Stefano Fanti, Susanne Krege, Pedro C. Lara, Mihai Dorin Vartolomei, Ashish M. Kamat, Jan Oldenburg, Peter Hoskin, Andrea Necchi, Barbara Alicja Jereczek-Fossa, George N. Thalmann, Bernard H. Bochner, Florian Roghmann, Horwich, A, Babjuk, M, Bellmunt, J, Bruins, Hm, De Reijke, Tm, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, Mj, Shariat, Sf, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, Pc, Bochner, Bh, Bolla, M, Boormans, Jl, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, Pjl, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, Jl, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, Jj, Gakis, G, Geavlete, B, Gontero, P, Grubmuller, B, Hafeez, S, Hansel, De, Hartmann, A, Hayne, D, Henry, Am, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, Ba, Jones, R, Kamat, Am, Khoo, V, Kiltie, Ae, Krege, S, Ladoire, S, Lara, Pc, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, Mc, Moschini, M, Mostafid, H, Muller, Ac, Muller, Cr, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, Jr, Oldenburg, J, Osanto, S, Oyen, Wjg, Pacheco-Figueiredo, L, Pappot, H, Patel, Mi, Pieters, Br, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, Je, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, Rj, Smits, A, Stenzl, A, Thalmann, Gn, Tombal, B, Turkbey, B, Lauridsen, Sv, Valdagni, R, Van der Heijden, Ag, Van Poppel, H, Vartolomei, Md, Veskimae, E, Vilaseca, A, Rivera, Fav, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, Witjes, Ja, Radiation Oncology, Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA., Universidade do Minho, APH - Personalized Medicine, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, Urology, Radiotherapy, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, and Pathology
- Subjects
0301 basic medicine ,Delphi Technique ,diagnosis ,International Cooperation ,Medicina Básica [Ciências Médicas] ,Delphi method ,Medizin ,CISPLATIN-INELIGIBLE PATIENTS ,Medical Oncology ,Delphi ,0302 clinical medicine ,PROGNOSTIC-FACTORS ,Multidisciplinary approach ,Surveys and Questionnaires ,consensu ,follow-up ,SINGLE-ARM ,Medicine ,Statistical analysis ,Multi stakeholder ,TRANSITIONAL-CELL CARCINOMA ,Societies, Medical ,computer.programming_language ,treatment ,Consensus conference ,Hematology ,3. Good health ,Europe ,diagnosi ,Oncology ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,030220 oncology & carcinogenesis ,Ciências Médicas::Medicina Básica ,Practice Guidelines as Topic ,TUMOR RESPONSE ,Special article ,bladder cancer ,RADICAL CYSTECTOMY ,LYMPHOCYTE RATIO ,medicine.medical_specialty ,METASTATIC UROTHELIAL CARCINOMA ,Urology ,Urinary Bladder ,education ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,LONG-TERM-SURVIVAL ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Stakeholder Participation ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,Journal Article ,Humans ,Oligometastatic disease ,Neoplasm Staging ,Science & Technology ,Bladder cancer ,business.industry ,medicine.disease ,030104 developmental biology ,Urinary Bladder Neoplasms ,consensus ,Family medicine ,business ,computer - Abstract
Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as 70% agreement and 15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach, The authors would like to thank Peter E. Clark from Atrium Health, Levine Cancer Institute, Charlotte, NC, USA, for his contribution to the Delphi survey. Angela Corstorphine of Kstorfin Medical Communications Ltd provided medical writing support with the preparation of this manuscript; this support was funded jointly by EAU and ESMO.
- Published
- 2019
39. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
- Author
-
Niall F. Davis, Muhammad Imran Omar, Alberto Briganti, Olivier Rouvière, James N'Dow, Ann Henry, Brett Cox, James W.F. Catto, Derya Tilki, Christopher J.D. Wallis, Maurizio Colecchia, Silke Gillessen, Steven MacLennan, Murali Varma, Thomas Van den Broeck, Philip Cornford, Susanne Vahr Lauridsen, J.P. Michiel Sedelaar, Nicola Fossati, Michael Lardas, Gemma Sancho Pardo, Paolo Dell'Oglio, André Deschamps, Nicolas Mottet, Lisa Moris, Marcus G. Cumberbatch, Thomas Wiegel, Raphaële Renard-Penna, Fabio Zattoni, James Donaldson, Phillip D. Stricker, Matthew Liew, Ivo G. Schoots, Stefano Fanti, Theodorus H. van der Kwast, Geert J.L.H. van Leenders, Nikolaos Grivas, Monique J. Roobol, Erik Briers, Hendrik Van Poppel, Karin Plass, Jeff Davies, Jonathan Richenberg, Maria De Santis, Jacques Irani, Daniel W. Lin, Shin Egawa, Tobias Gross, Peter Paul M. Willemse, Roderick C.N. van den Bergh, Alberto Bossi, Henk G. van der Poel, Chris H. Bangma, Maria J. Ribal, Giorgio Gandaglia, Alexandre Ingels, Karl H. Pang, Morgan Rouprêt, Robert Shepherd, Jeremy Grummet, Thomas B. Lam, Malcolm David Mason, Catherine Paterson, Karel Tim Buddingh, Christian D. Fankhauser, Ruud Baanders, Anders Bjartell, Philippe D. Violette, Karen Wilkinson, Lam, T. B. L., Maclennan, S., Willemse, P. -P. M., Mason, M. D., Plass, K., Shepherd, R., Baanders, R., Bangma, C. H., Bjartell, A., Bossi, A., Briers, E., Briganti, A., Buddingh, K. T., Catto, J. W. F., Colecchia, M., Cox, B. W., Cumberbatch, M. G., Davies, J., Davis, N. F., De Santis, M., Dell'Oglio, P., Deschamps, A., Donaldson, J. F., Egawa, S., Fankhauser, C. D., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Gross, T., Grummet, J. P., Henry, A. M., Ingels, A., Irani, J., Lardas, M., Liew, M., Lin, D. W., Moris, L., Omar, M. I., Pang, K. H., Paterson, C. C., Renard-Penna, R., Ribal, M. J., Roobol, M. J., Roupret, M., Rouviere, O., Sancho Pardo, G., Richenberg, J., Schoots, I. G., Sedelaar, J. P. M., Stricker, P., Tilki, D., Vahr Lauridsen, S., van den Bergh, R. C. N., Van den Broeck, T., van der Kwast, T. H., van der Poel, H. G., van Leenders, G. J. L. H., Varma, M., Violette, P. D., Wallis, C. J. D., Wiegel, T., Wilkinson, K., Zattoni, F., N'Dow, J. M. O., Van Poppel, H., Cornford, P., Mottet, N., Urology, Radiology & Nuclear Medicine, Pathology, and Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N.
- Subjects
Male ,medicine.medical_specialty ,Localised prostate cancer ,Urology ,education ,030232 urology & nephrology ,Delphi method ,Reclassification ,Outcome measures ,Time-to-Treatment ,Outcome measure ,03 medical and health sciences ,Prostate cancer ,Active surveillance and monitoring ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Consensus group meeting ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,medicine ,Humans ,610 Medicine & health ,Clinical practice guideline ,Curative intent ,Clinical Oncology ,Eligibility ,business.industry ,Follow-up ,Prostatic Neoplasms ,Consensus statements ,Guideline ,Deferred treatment with curative intent ,medicine.disease ,Clinical practice guidelines ,Delphi survey ,Deferred treatment ,Consensus statement ,030220 oncology & carcinogenesis ,Family medicine ,business - Abstract
Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. (C) 2019 Published by Elsevier B.V. on behalf of European Association of Urology.
- Published
- 2019
40. Model studies on sound radiation from metal and periodic structures by Schlieren optics
- Author
-
Plass, K
- Published
- 1971
- Full Text
- View/download PDF
41. A1004 - International opinions on grading of urothelial carcinoma: A survey among European Association of Urology and International Society of Urological Pathology members.
- Author
-
Beijert, I.J., Cheng, L., Liedberg, F., Plass, K., Gontero, P., Ribal, M.J., Babjuk, M., Black, P.C., Kamat, A.M., Algaba, F., Berman, D.M., Hartmann, A., Masson-Lecomte, A., Rouprêt, M., Lopez-Beltran, A., Shariat, S.F., Mostafid, H., Burger, M., Palou, J., and Compérat, E.M.
- Subjects
- *
TRANSITIONAL cell carcinoma , *PATHOLOGY - Published
- 2023
- Full Text
- View/download PDF
42. IMAGINE-IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines
- Author
-
Philip Cornford, Emma Jane Smith, Steven MacLennan, Nuno Pereira-Azevedo, Monique J. Roobol, Nicolaas Lumen, Louise Fullwood, Eilidh Duncan, Jennifer Dunsmore, Karin Plass, Maria J. Ribal, Thomas Knoll, Anders Bjartell, Hendrick Van Poppel, James N’Dow, Alberto Briganti, Karl Dorfinger, Irene Resch, Mischinger Johannes, Isabel Heidegger, Christophe Assenmacher, Thierry Roumeguère, Karel Decaestecker, Lieven Goeman, Thomas Adams, Marincho Georgiev, Krassimir Yanev, Aleksandar Timev, Igor Tomašković, Tomislav Kuliš, Stavros Charalampous, Dimitris Kontaxis, Marko Babjuk, Roman Zachoval, Tomáš Pitra, Vojtěch Novák, Lars Lund, Martin Kivi, Peep Baum, Toomas Tamm, Pritt Veskimae, Rauno Okas, Kanerva Lahdensuo, Kimmo Taari, Heikki Seikkula, Pyry Jämsä, Xavier Gamé, George Fournier, Alexandre Ingels, Gaelle Fiard, Guillaume Ploussard, Jens Rassweiler, Stefanie Schmidt, Jennifer Kranz, Susanne Krege, Ioannis Gkialas, Anthanasios Dellis, Nikolaos Ferakis, Dionysios Mitropoulos, Peter Ryan, John Paul Sweeney, Eamonn Rogers, Derek Hennessy, Niall. F. Davis, Walter Artibani, Francesco Porpiglia, Salvatore Giuseppe Voce, Maurizio Brausi, Maria A. Cerruto, Francesco Esperto, Matteo Manfredi, Mindaugas Jievaltas, Aušvydas Patašius, Albertas Čekauskas, Stasys Auškalnis, Peter Mulders, Frank Martens, Kathleen W.M. D'Hauwers, Piotr Chlosta, Anna Katarzyna Czech, Katarzyna Gronostaj, Mikołaj Przydacz, Pedro Coelho Nunes, Luís Abranches-Monteiro, Ricardo Pereira e Silva, Frederica Furriel, Pedro Gomes Monteiro, Ioanel Sinescu, Cristian Surcel, Catalin Baston, Robert Ionut Stoica, Vlad Olaru, Boris Kollárik, Ivan Mincik, Ľuboš Rybár, Viktor Kováčik, Ivan Perečinský, Boris Kosuta, Marko Zupancic, Milena Taskovska, Uros Kacjan, Andraz Miklavzina, Manuel Esteban Fuertes, Mario Alvarez-Maestro, Antoni Vilaseca, Rodrigo García-Baquero, Lotta Renström Koskela, Johan Styrke, Gezim Galiqi, Bilbil Hoxha, Evisa Zhapa, Rezart Xhani, Sergey Fanarjyan, Ruben Hovhannisyan, Avoyan E. Armen, Rafael Badalyan, Mustafa Hiroš, Davor Tomić, Damir Aganović, Archil Chkhotua, David Nikoleishvili, Zara Tchanturaia, Sigurdur Gudjónsson, Eirikur Orri Gudmundsson, Rafn Hilmarsson, Emil Ceban, Vitalii Ghicavii, Adrian Tanase, Vladislav Vasiliev, Dragoljub Perovic, Marko Vukovic, Stanisavljevic Rade, Nenad Radovic, Emil Nasufovic, Yuri Alyaev, Igor Korneyev, Sergei Kotov, Vigen Malkhasyan, Dragoslav Basic, Miodrag Aćimović, Saša Vojinov, Aleksandar Vuksanovic, Uroš Bumbaširević, Bojan Čegar, Branko Stanković, Hansjörg Danuser, Tullio Sulser, Valentin Zumstein, Ates Kadioglu, Hakan Kilicarslan, Nusret Can Cilesiz, Erhan Demirelli, Bülent Önal, Aydin Mungan, Serdar Tekgül, Levent Türkeri, Adil Esen, Oleksandr Shulyak, Sergiy Vozianov, Alexandr Shulyak, Serhii Volkov, Andrii Nesterchuk, Urology, Cornford, P., Smith, E. J., Maclennan, S., Pereira-Azevedo, N., Roobol, M. J., Lumen, N., Fullwood, L., Duncan, E., Dunsmore, J., Plass, K., Ribal, M. J., Knoll, T., Bjartell, A., Van Poppel, H., N'Dow, J., and Briganti, A.
- Subjects
Supplementary data ,Physicians' ,Impact assessment ,business.industry ,Urology ,030232 urology & nephrology ,MEDLINE ,Guideline ,Practice Patterns ,Clinical Practice ,Europe ,Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10] ,03 medical and health sciences ,Frontier ,0302 clinical medicine ,Reconstructive and regenerative medicine Radboud Institute for Molecular Life Sciences [Radboudumc 10] ,Nursing ,030220 oncology & carcinogenesis ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,Medicine ,Humans ,Guideline Adherence ,Practice Patterns, Physicians' ,Baseline (configuration management) ,business - Abstract
Contains fulltext : 237261.pdf (Publisher’s version ) (Closed access) Adherence to national and international clinical practice guidelines is suboptimal throughout Europe. The European Association of Urology Guidelines Office project "IMAGINE" (IMpact Assessment of Guidelines Implementation and Education) has been developed to measure baseline adherence to urological guideline recommendations across Europe and to identify issues that drive nonadherence.
- Published
- 2021
43. Male Sexual and Reproductive Health—Does the Urologist Have a Role in Addressing Gender Inequality in Life Expectancy?
- Author
-
Ates Kadioglu, Carlo Bettocchi, Juan Ignatio Martínez Salamanca, Ege Can Serefoglu, Giovanni Corona, Karin Plass, Tharu Tharakan, Joana Carvalho, Paolo Verze, Julie Darraugh, James N'Dow, Suks Minhas, Ulla Nordström Joensen, Hugh Jones, Andrea Salonia, Tharakan, T., Bettocchi, C., Carvalho, J., Corona, G., Joensen, U. N., Jones, H., Kadioglu, A., Martinez Salamanca, J. I., Serefoglu, E. C., Verze, P., Darraugh, J., Plass, K., N'Dow, J., Salonia, A., Minhas, S., and Faculdade de Psicologia e de Ciências da Educação
- Subjects
Male ,medicine.medical_specialty ,Life expectancy ,Urology ,Testosterone late-onset hypogonadism ,030232 urology & nephrology ,Legislation ,World health ,03 medical and health sciences ,0302 clinical medicine ,Life Expectancy ,Sex Factors ,medicine ,Humans ,Gender gap ,Physician's Role ,Androgen deprivation ,Cardiovascular disease ,Diabetes ,Male infertility ,Metabolic syndrome ,Prostate cancer ,Testosterone replacement therapy ,Female ,Men's Health ,Reproductive Health ,Sexual Health ,Reproductive health ,Gender inequality ,business.industry ,Public health ,030220 oncology & carcinogenesis ,Natural phenomenon ,business - Abstract
Despite considerable public health initiatives in the past century, there remains a significant gender inequality in life expectancy. The Global Burden of Diseases study has highlighted that the life expectancy for men is 70.5 years, compared with 75.6 years for women. This discrepancy in mortality appears to be related to a disproportionately higher number of preventable and premature male deaths. Whilst there has been an increased focus on men's health, as evidenced by the establishment of men's health charities and governmental legislation promoting equality, a recent World Health Organization report has highlighted that there is still a prevailing misconception that the higher rate of premature mortality amongst men is a natural phenomenon. We explore the association of male sexual and reproductive health–related diseases and the potential role of a urologist in addressing gender inequality in life expectancy. Patient summary: In this report, we discuss the causes for the gender gap in life expectancy and highlight that men continue to have a higher rate of premature death than women, which is associated with diseases of the male reproductive system. Furthermore, this not only appears to be related to a number of metabolic and lifestyle factors, but may also be the result of the increased risk of cancer in men with sexual and reproductive health–related diseases. Globally, the life expectancy for men is 5.1 yr less than that of women. We describe the association between diseases of the male reproductive system and cardiovascular disease and cancers, and highlight the important role of a urologist in reducing premature male death.
- Published
- 2020
44. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
- Author
-
Bogdan Geavlete, Stefano Fanti, Susanne Krege, Alberto Briganti, Harry W. Herr, Shaista Hafeez, Mark Frydenberg, Marek Babjuk, Willem de Blok, Antti Salminen, Maria De Santis, Yann Neuzillet, Arnulf Stenzl, Joost L. Boormans, Hein Van Poppel, Karel Decaestecker, Vibeke Løgager, Jorg R. Oddens, Silke Gillessen, Pedro C. Lara, Berardino De Bari, Baris Turkbey, Andrew K. Williams, Thomas Wiegel, Mihai Dorin Vartolomei, Robert Jones, Riccardo Valdagni, Vincent Khoo, Ashish M. Kamat, Christoph R. Müller, Georgios Gakis, Neeraj Agarwal, Annemarie Leliveld, Franklin A. Vives Rivera, Robert Jan Smeenk, Luís Pacheco-Figueiredo, H. Maxim Bruins, Juan Palou, Jorge Huguet, Konstantinos Dimitropoulos, Jonathan E. Rosenberg, Carl Salembier, Ken Herrmann, Iris Brummelhuis, Morgan Rouprêt, Helle Pappot, Susanne Osanto, Shahrokh F. Shariat, Anita Smits, Susanne Vahr Lauridsen, Manish I. Patel, Theo H. van der Kwast, Paul Sargos, Michel Bolla, Karin Plass, Jurgen J. Fütterer, Hugh Mostafid, Olivier Rouvière, Valérie Fonteyne, Erik Veskimäe, Bradley R. Pieters, Richard P. Meijer, Anne E. Kiltie, Tom J.H. Arends, Arndt Hartmann, Amir Sherif, Antoni Vilaseca, Stéphane Culine, Wim J.G. Oyen, Evanguelos Xylinas, Daniel Castellano, Shomik Sengupta, James N'Dow, Maria J. Ribal, Mesut Remzi, Richard Zigeuner, A. Müller, Richard Cathomas, Joaquim Bellmunt, Nicholas D. James, Paolo Gontero, Pieter De Visschere, Eva Compérat, Alison Birtle, Margitta Retz, Dickon Hayne, Michael Rink, Virginia Hernández, J. Alfred Witjes, Marco Moschini, J. Domínguez-Escrig, Yohann Loriot, Estefania Linares-Espinós, Peter C. Black, Alberto Bossi, Bertrand Tombal, Sylvain Ladoire, Aristotle Bamias, Ananya Choudhury, Simon J. Crabb, Steven MacLennan, Peter Wiklund, Antoine G. van der Heijden, Arturo Chiti, Bernhard Grubmüller, Barbara Alicja Jereczek-Fossa, Alan Horwich, George N. Thalmann, Bernard H. Bochner, Florian Roghmann, Max Bürger, Jan Oldenburg, Peter Hoskin, Andrea Necchi, Jonathan Richenberg, Anja Lorch, Peter Paul M. Willemse, Donna E. Hansel, M. Carmen Mir, Thomas Powles, Theo M. de Reijke, Ann Henry, Witjes, J. A., Babjuk, M., Bellmunt, J., Bruins, H. M., De Reijke, T. M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M. J., Shariat, S. F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P. C., Bochner, B. H., Bolla, M., Boormans, J. L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Comperat, E., Crabb, S., Culine, S., De Bari, B., De Blok, W., De Visschere, P. J. L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J. L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J. J., Gakis, G., Geavlete, B., Gontero, P., Grubmuller, B., Hafeez, S., Hansel, D. E., Hartmann, A., Hayne, D., Henry, A. M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B. A., Jones, R., Kamat, A. M., Khoo, V., Kiltie, A. E., Krege, S., Ladoire, S., Lara, P. C., Leliveld, A., Linares-Espinos, E., Logager, V., Lorch, A., Loriot, Y., Meijer, R., Mir, M. C., Moschini, M., Mostafid, H., Muller, A. -C., Muller, C. R., N'Dow, J., Necchi, A., Neuzillet, Y., Oddens, J. R., Oldenburg, J., Osanto, S., Oyen, W. J. G., Pacheco-Figueiredo, L., Pappot, H., Patel, M. I., Pieters, B. R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J. E., Roupret, M., Rouviere, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R. J., Smits, A., Stenzl, A., Thalmann, G. N., Tombal, B., Turkbey, B., Lauridsen, S. V., Valdagni, R., Van Der Heijden, A. G., Van Poppel, H., Vartolomei, M. D., Veskimae, E., Vilaseca, A., Rivera, F. A. V., Wiegel, T., Wiklund, P., Willemse, P. -P. M., Williams, A., Zigeuner, R., Horwich, A., Urology, APH - Personalized Medicine, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, Radiotherapy, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, and UCL - (SLuc) Service d'urologie
- Subjects
medicine.medical_specialty ,Bladder cancer ,business.industry ,Urology ,030232 urology & nephrology ,MEDLINE ,Cancer ,Regret ,medicine.disease ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Medicine ,Urologia ,University medical ,Bufeta -- Càncer ,Protocols clínics ,business - Abstract
The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands
- Published
- 2020
45. European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management
- Author
-
Julie Darraugh, Thomas Knoll, Alberto Briganti, Maria J. Ribal, Philip Cornford, Emma Jane Smith, Richard Sylvester, Robert Shepherd, Anders Bjartell, Karin Plass, James N'Dow, Nicolaas Lumen, Hendrik Van Poppel, Smith, E. J., Plass, K., Darraugh, J., Shepherd, R., Briganti, A., Cornford, P., Knoll, T., Lumen, N., N'Dow, J., Ribal, M. J., Sylvester, R., van Poppel, H., and Bjartell, A.
- Subjects
Process management ,Process (engineering) ,business.industry ,Conflict of Interest ,Association (object-oriented programming) ,Urology ,030232 urology & nephrology ,MEDLINE ,Conflict of interest ,Guidelines as Topic ,Disclosure ,Europe ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Medicine ,Humans ,Systematic process ,Guideline development ,business ,Societies, Medical - Abstract
Conflicts of interest (COIs) can potentially introduce a risk of bias into the assessment of evidence and the formulation of recommendations for guidelines. It is essential that a systematic process for the disclosure and management of COIs is adopted to minimise potential bias in the guideline development process.
- Published
- 2019
46. Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer
- Author
-
Nicola Fossati, Karel Tim Buddingh, Malcolm David Mason, Karin Plass, Christian D. Fankhauser, Steven MacLennan, Michael Lardas, James N'Dow, Henk G. van der Poel, Hendrik Van Poppel, Thomas B. Lam, Philip Cornford, Thomas Van den Broeck, Alexandre Ingels, Thomas Wiegel, Niall F. Davis, Peter-Paul M. Willemse, Catherine Paterson, Olivier Rouvière, Silke Gillessen, Lisa Moris, Fabio Zattoni, Marcus G. Cumberbatch, Matthew Liew, Theodorus H. van der Kwast, Ivo G. Schoots, Jeremy Grummet, Tobias Gross, N. Grivas, Stefano Fanti, Roderick C.N. van den Bergh, Ann Henry, Paolo Dell'Oglio, N. Mottet, James Donaldson, Muhammad Imran Omar, Derya Tilki, Maria De Santis, Erik Briers, Karl H. Pang, Radiology & Nuclear Medicine, Pathology, and Lam TBL, MacLennan S, Plass K, Willemse PM, Mason MD, Cornford P, Donaldson J, Davis NF, Dell'Oglio P, Fankhauser C, Grivas N, Ingels A, Lardas M, Liew M, Pang KH, Paterson C, Omar MI, Zattoni F, Buddingh KT, Van den Broeck T, Cumberbatch MG, Fossati N, Gross T, Moris L, Schoots IG, van den Bergh RCN, Briers E, Fanti S, De Santis M, Gillessen S, Grummet JP, Henry AM, van der Poel HG, van der Kwast TH, Rouvière O, Tilki D, Wiegel T, N'Dow J, Van Poppel H, Mottet N.
- Subjects
Research design ,Male ,medicine.medical_specialty ,Consensus ,Letter ,Delphi Technique ,Consensus Development Conferences as Topic ,Urology ,education ,030232 urology & nephrology ,Delphi method ,MEDLINE ,Prostatic Neoplasms/pathology ,Evidence-Based Medicine ,Humans ,Medical Oncology ,Multicenter Studies as Topic ,Prostatic Neoplasms ,Systematic Reviews as Topic ,Treatment Outcome ,Research Design ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,medicine ,610 Medicine & health ,computer.programming_language ,Protocol (science) ,business.industry ,Prostate Cancer ,Urology/standards ,Stakeholder ,Evidence-based medicine ,Guideline ,030220 oncology & carcinogenesis ,Family medicine ,Medical Oncology/standards ,business ,computer ,Delphi ,Multicenter Studies as Topic/methods - Abstract
Deferred active treatment (DAT) strategies, including active surveillance and active monitoring, are a recognised management option for men with localised low-risk prostate cancer. However, there is uncertainty due to heterogeneity of patient selection criteria, follow-up and monitoring characteristics, reclassification thresholds, and which outcome measures should be prioritised. This protocol describes a study led by the European Association of Urology (EAU) Prostate Cancer Guidelines Panel in conjunction with other guideline organisations and societies to develop consensus statements for all domains of deferred active treatment. The project is divided into 3 sequential phases: (1) Systematic review of studies reporting on DAT in order to summarise and define range of heterogeneity regarding all domains; (2) Two-round Delphi online survey involving a large, international panel of healthcare professionals (HCPs) and patients to initiate consensus; and (3) Consensus group meeting involving representatives from HCP and patient stakeholder groups to finalise the consensus process. The consensus statements are expected to be adopted by clinical practice guidelines in order to standardise and guide practice for clinicians and researchers until better evidence emerges. Patient summary: We describe a project aimed at standardising elements of practice in active surveillance/monitoring for early localised prostate cancer, because currently there is great variation and uncertainty regarding how best to conduct them. This will be achieved through a structured process of agreement (i.e. consensus) amongst a large, international panel of healthcare professionals and patients.
- Published
- 2019
47. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
- Author
-
Beijert IJ, Hentschel AE, Bründl J, Compérat EM, Plass K, Rodríguez O, Subiela Henríquez JD, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Bruins HM, Runneboom W, Herdegen S, Breyer J, Brisuda A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Contieri R, Mertens LS, Claps F, Masson-Lecomte A, Liedberg F, Cohen D, Lunelli L, Cussenot O, El Sheikh S, Volanis D, Côté JF, Rouprêt M, Haitel A, Shariat SF, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, Kiemeney LALM, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Ribal MJ, van der Kwast TH, Babjuk M, Sylvester RJ, and van Rhijn BWG
- Subjects
- Humans, Prognosis, Urologic Surgical Procedures, Urinary Bladder surgery, Urinary Bladder pathology, Cystectomy, Neoplasm Staging, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms surgery, Urinary Bladder Neoplasms pathology
- Abstract
Purpose: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial resection, restaging-TURB is required if the first resection was macroscopically complete but contained no detrusor muscle (DM) and second-TURB is advised for all completely resected T1-tumors with DM in the resection specimen. This study assessed the long-term outcomes after repeat-, second-, and restaging-TURB in T1-NMIBC patients., Methods: Individual patient data with tumor characteristics of 1660 primary T1-patients (muscle-invasion at re-TURB omitted) diagnosed from 1990 to 2018 in 17 hospitals were analyzed. Time to recurrence, progression, death due to bladder cancer (BC), and all causes (OS) were visualized with cumulative incidence functions and analyzed by log-rank tests and multivariable Cox-regression models stratified by institution., Results: Median follow-up was 45.3 (IQR 22.7-81.1) months. There were no differences in time to recurrence, progression, or OS between patients undergoing restaging (135 patients), second (644 patients), or repeat-TURB (84 patients), nor between patients who did or who did not undergo second or restaging-TURB. However, patients who underwent repeat-TURB had a shorter time to BC death compared to those who had second- or restaging-TURB (multivariable HR 3.58, P = 0.004)., Conclusion: Prognosis did not significantly differ between patients who underwent restaging- or second-TURB. However, a worse prognosis in terms of death due to bladder cancer was found in patients who underwent repeat-TURB compared to second-TURB and restaging-TURB, highlighting the importance of separately evaluating different indications for re-TURB., (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2024
- Full Text
- View/download PDF
48. From BPH to male LUTS: a 20-year journey of the EAU guidelines.
- Author
-
Gravas S, Malde S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Mamoulakis C, Rieken M, Sakalis VI, Schouten N, Smith EJ, Speakman MJ, Tikkinen KAO, Alivizatos G, Bach T, Bachmann A, Descazeaud A, Desgrandchamps F, Drake M, Emberton M, Kyriazis I, Madersbacher S, Michel MC, N'Dow J, Perachino M, Plass K, Rioja Sanz C, Umbach R, de Wildt M, Oelke M, and de la Rosette JJMCH
- Subjects
- Humans, Male, Prostatic Neoplasms, Prostatic Hyperplasia complications, Prostatic Hyperplasia diagnosis, Prostatic Hyperplasia epidemiology, Lower Urinary Tract Symptoms diagnosis, Lower Urinary Tract Symptoms epidemiology, Lower Urinary Tract Symptoms etiology
- Published
- 2024
- Full Text
- View/download PDF
49. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members.
- Author
-
Beijert IJ, Cheng L, Liedberg F, Plass K, Williamson SR, Gontero P, Ribal MJ, Babjuk M, Black PC, Kamat AM, Algaba F, Berman DM, Hartmann A, Masson-Lecomte A, Rouprêt M, Lopez-Beltran A, Samaratunga H, Shariat SF, Mostafid AH, Varma M, Shen S, Burger M, Tsuzuki T, Palou J, Compérat EM, Sylvester RJ, van der Kwast TH, van Rhijn BWG, and Downes MR
- Abstract
Background: Grade of non-muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1-3, and WHO2004 categories: papillary urothelial neoplasm of low malignant potential [PUNLMP], low-grade [LG], high-grade [HG] carcinoma) are used., Objective: To ask the European Association of Urology (EAU) and International Society of Urological Pathology (ISUP) members regarding their current practice and preferences of grading systems., Design Setting and Participants: A web-based, anonymous questionnaire with ten questions on grading of NMIBC was created. The members of EAU and ISUP were invited to complete an online survey by the end of 2021. Thirteen experts had previously answered the same questions., Outcome Measurements and Statistical Analysis: The submitted answers from 214 ISUP members, 191 EAU members, and 13 experts were analyzed., Results and Limitations: Currently, 53% use only the WHO2004 system and 40% use both systems. According to most respondents, PUNLMP is a rare diagnosis with management similar to Ta-LG carcinoma. The majority (72%) would consider reverting back to WHO1973 if grading criteria were more detailed. Separate reporting of WHO1973-G3 within WHO2004-HG would influence clinical decisions for Ta and/or T1 tumors according the majority (55%). Most respondents preferred a two-tier (41%) or a three-tier (41%) grading system. The current WHO2004 grading system is supported by a minority (20%), whereas nearly half (48%) supported a hybrid three- or four-tier grading system composed of both WHO1973 and WHO2004. The survey results of the experts were comparable with ISUP and EAU respondents., Conclusions: Both the WHO1973 and the WHO2004 grading system are still widely used. Even though opinions on the future of bladder cancer grading were strongly divided, there was limited support for WHO1973 and WHO2004 in their current formats, while the hybrid (three-tier) grading system with LG, HG-G2, and HG-G3 as categories could be considered the most promising alternative., Patient Summary: Grading of non-muscle-invasive bladder cancer (NMIBC) is a matter of ongoing debate and lacks international consensus. We surveyed urologists and pathologists of European Association of Urology and International Society of Urological Pathology on their preferences regarding NMIBC grading to generate a multidisciplinary dialogue. Both the "old" World Health Organization (WHO) 1973 and the "new" WHO2004 grading schemes are still used widely. However, continuation of both the WHO1973 and the WHO2004 system showed limited support, while a hybrid grading system composed of both the WHO1973 and the WHO2004 classification system may be considered a promising alternative., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
50. Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488].
- Author
-
Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Max Bruins H, Bründl J, van der Kwast TH, Brisuda A, Rubio-Briones J, Seles M, Hentschel AE, Kusuma VRM, Huebner N, Cotte J, Mertens LS, Volanis D, Cussenot O, Subiela Henríquez JD, de la Peña E, Pisano F, Pešl M, van der Heijden AG, Herdegen S, Zlotta AR, Hacek J, Calatrava A, Mannweiler S, Bosschieter J, Ashabere D, Haitel A, Côté JF, El Sheikh S, Lunelli L, Algaba F, Alemany I, Soria F, Runneboom W, Breyer J, Nieuwenhuijzen JA, Llorente C, Molinaro L, Hulsbergen-van de Kaa CA, Evert M, Kiemeney LALM, N'Dow J, Plass K, Čapoun O, Soukup V, Dominguez-Escrig JL, Cohen D, Palou J, Gontero P, Burger M, Zigeuner R, Mostafid AH, Shariat SF, Rouprêt M, Compérat EM, Babjuk M, and van Rhijn BWG
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.